Regulatory Bayer gets swift review for Kerendia in type 1 diabetes PharmaphorumFDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum FDA starts a priority review of Bayer’s Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies. Metabolic & GLP-1 Read full story Post navigation Previous: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPDNext: FUJIFILM opens new iPSC facility in Madison, US Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026